Biotin-14-dATP
To Order Contact us: lieven@wlsolutions.be
dATP |
||
| K6011101-100 | 100 ul (100 mM) | EUR 115.2 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
||
dATP |
||
| K6011101-400 | 400 ul (100 mM) | EUR 139.2 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
||
Cyanine 5-dATP [Cy5-dATP] |
||
| 17038 | 25 nmoles | EUR 102 |
Heart Lysate (14 Days Old) |
||
| 1401-14 | 0.1 mg | EUR 229.2 |
|
Description: Heart tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Lung Lysate (14 Days Old) |
||
| 1402-14 | 0.1 mg | EUR 229.2 |
|
Description: Lung tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Brain Lysate (14 Days Old) |
||
| 1403-14 | 0.1 mg | EUR 229.2 |
|
Description: Brain tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Liver Lysate (14 Days Old) |
||
| 1404-14 | 0.1 mg | EUR 229.2 |
|
Description: Liver tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Kidney Lysate (14 Days Old) |
||
| 1405-14 | 0.1 mg | EUR 229.2 |
|
Description: Kidney tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Spleen Lysate (14 Days Old) |
||
| 1406-14 | 0.1 mg | EUR 229.2 |
|
Description: Spleen tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Thymus Lysate (14 Days Old) |
||
| 1409-14 | 0.1 mg | EUR 229.2 |
|
Description: Thymus tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Stomach Lysate (14 Day Old) |
||
| 1415-14 | 0.1 mg | EUR 229.2 |
|
Description: Stomach tissue lysate (14 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Skin Lysate (14 Days Old) |
||
| 1419-14 | 0.1 mg | EUR 229.2 |
|
Description: Skin tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
Eye Lysate (14 Days Old) |
||
| 1420-14 | 0.1 mg | EUR 229.2 |
|
Description: Eye tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
||
dATP, 100mM |
||
| BIO-39036 | 25µmol, (1 x 250µl) | Ask for price |
Caspase 14 (CASP14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAA457Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Caspase 14 (CASP14). This antibody is labeled with Biotin. |
||
Caspase 14 (CASP14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAA457Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Caspase 14 (CASP14). This antibody is labeled with Biotin. |
||
Caspase 14 (CASP14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAA457Mu02-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Caspase 14 (CASP14). This antibody is labeled with Biotin. |
||
Caspase 14 (CASP14) Polyclonal Antibody (Rat), Biotinylated |
||
| 4-PAA457Ra01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Rat Caspase 14 (CASP14). This antibody is labeled with Biotin. |
||
Keratin 14 (KRT14) Polyclonal Antibody (Human, Rat), Biotinylated |
||
| 4-PAA522Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Rat Keratin 14 (KRT14). This antibody is labeled with Biotin. |
||
Keratin 14 (KRT14) Polyclonal Antibody (Human, Rat), Biotinylated |
||
| 4-PAA522Ra01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Rat Keratin 14 (KRT14). This antibody is labeled with Biotin. |
||
Glucose Transporter 14 (GLUT14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAE354Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Glucose Transporter 14 (GLUT14). This antibody is labeled with Biotin. |
||
Glucose Transporter 14 (GLUT14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAE354Hu02-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Glucose Transporter 14 (GLUT14). This antibody is labeled with Biotin. |
||
Glucose Transporter 14 (GLUT14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAE354Hu03-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Glucose Transporter 14 (GLUT14). This antibody is labeled with Biotin. |
||
Kallikrein 14 (KLK14) Polyclonal Antibody (Human, Pig), Biotinylated |
||
| 4-PAD374Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Pig Kallikrein 14 (KLK14). This antibody is labeled with Biotin. |
||
Matrix Metalloproteinase 14 (MMP14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAC056Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Matrix Metalloproteinase 14 (MMP14). This antibody is labeled with Biotin. |
||
Matrix Metalloproteinase 14 (MMP14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAC056Hu02-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Matrix Metalloproteinase 14 (MMP14). This antibody is labeled with Biotin. |
||
Matrix Metalloproteinase 14 (MMP14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAC056Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Matrix Metalloproteinase 14 (MMP14). This antibody is labeled with Biotin. |
||
Suppression Of Tumorigenicity 14 (ST14) Monoclonal Antibody (Human), Biotinylated |
||
| 4-MAP657Hu21-Biotin |
|
|
|
Description: A Mouse monoclonal antibody against Human Suppression Of Tumorigenicity 14 (ST14). This antibody is labeled with Biotin. |
||
Cluster Of Differentiation 14 (CD14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAA685Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Cluster Of Differentiation 14 (CD14). This antibody is labeled with Biotin. |
||
Cluster Of Differentiation 14 (CD14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAA685Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Cluster Of Differentiation 14 (CD14). This antibody is labeled with Biotin. |
||
Cluster Of Differentiation 14 (CD14) Polyclonal Antibody (Pig), Biotinylated |
||
| 4-PAA685Po01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Pig Cluster Of Differentiation 14 (CD14). This antibody is labeled with Biotin. |
||
Cluster Of Differentiation 14 (CD14) Polyclonal Antibody (Rat), Biotinylated |
||
| 4-PAA685Ra01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Rat Cluster Of Differentiation 14 (CD14). This antibody is labeled with Biotin. |
||
Glucose Transporter 14 (GLUT14) Polyclonal Antibody (Human, Mouse), Biotinylated |
||
| 4-PAE354Hu04-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Mouse Glucose Transporter 14 (GLUT14). This antibody is labeled with Biotin. |
||
Ubiquitin Specific Peptidase 14 (USP14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAF134Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Ubiquitin Specific Peptidase 14 (USP14). This antibody is labeled with Biotin. |
||
Suppression Of Tumorigenicity 14 (ST14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAP657Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Suppression Of Tumorigenicity 14 (ST14). This antibody is labeled with Biotin. |
||
dATP, 100mM, 1ml |
||
| 2013A-1ML | EUR 184.8 | |
dATP (100 mM) |
||
| P034-01 | 1 ml | EUR 172.8 |
Keratin 14 (KRT14) Polyclonal Antibody (Human, Mouse, Guinea pig), Biotinylated |
||
| 4-PAA522Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Mouse, Guinea pig Keratin 14 (KRT14). This antibody is labeled with Biotin. |
||
Heat Shock 70kDa Protein 14 (HSPA14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAD503Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Heat Shock 70kDa Protein 14 (HSPA14). This antibody is labeled with Biotin. |
||
PR Domain Containing Protein 14 (PRDM14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAP332Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human PR Domain Containing Protein 14 (PRDM14). This antibody is labeled with Biotin. |
||
Mitogen Activated Protein Kinase 14 (MAPK14) Polyclonal Antibody (Rat, Mouse), Biotinylated |
||
| 4-PAB206Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Rat, Mouse Mitogen Activated Protein Kinase 14 (MAPK14). This antibody is labeled with Biotin. |
||
Chemokine C-C-Motif Ligand 14 (CCL14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAB122Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Chemokine C-C-Motif Ligand 14 (CCL14). This antibody is labeled with Biotin. |
||
Chemokine C-C-Motif Ligand 14 (CCL14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAB122Hu02-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Chemokine C-C-Motif Ligand 14 (CCL14). This antibody is labeled with Biotin. |
||
17-Beta-Hydroxysteroid Dehydrogenase Type 14 (HSD17b14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAF175Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human 17-Beta-Hydroxysteroid Dehydrogenase Type 14 (HSD17b14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAA827Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAA827Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) Polyclonal Antibody (Rat), Biotinylated |
||
| 4-PAA827Ra01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Rat Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAD926Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) Polyclonal Antibody (Mouse), Biotinylated |
||
| 4-PAD926Mu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14). This antibody is labeled with Biotin. |
||
Myosin Heavy Chain 14, Non Muscle (MYH14) Polyclonal Antibody (Human, Rat), Biotinylated |
||
| 4-PAD454Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Rat Myosin Heavy Chain 14, Non Muscle (MYH14). This antibody is labeled with Biotin. |
||
Protein Tyrosine Phosphatase, Non Receptor Type 14 (PTPN14) Polyclonal Antibody (Rat), Biotinylated |
||
| 4-PAD594Ra01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Rat Protein Tyrosine Phosphatase, Non Receptor Type 14 (PTPN14). This antibody is labeled with Biotin. |
||
Purinergic Receptor P2Y, G Protein Coupled 14 (P2RY14) Polyclonal Antibody (Human), Biotinylated |
||
| 4-PAG084Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human Purinergic Receptor P2Y, G Protein Coupled 14 (P2RY14). This antibody is labeled with Biotin. |
||
Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) Monoclonal Antibody (Human, Rat), Biotinylated |
||
| 4-MAA827Hu21-Biotin |
|
|
|
Description: A Mouse monoclonal antibody against Human, Rat Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14). This antibody is labeled with Biotin. |
||
Sialic Acid Binding Ig Like Lectin 14 (SIGLEC14) Polyclonal Antibody (Human, Rat), Biotinylated |
||
| 4-PAS344Hu01-Biotin |
|
|
|
Description: A Rabbit polyclonal antibody against Human, Rat Sialic Acid Binding Ig Like Lectin 14 (SIGLEC14). This antibody is labeled with Biotin. |
||
Biotin-Somatostatin-14 |
||
| 5-00820 | 4 x 1mg | Ask for price |
dATP, dCTP, dGTP, dTTP |
||
| K6011100-100 | 4x 100 ul (100 mM) | EUR 139.2 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
||
dATP, dCTP, dGTP, dTTP |
||
| K6011100-1000 | 4x1 ml (100 mM) | EUR 620.4 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
||
dATP, dCTP, dGTP, dTTP |
||
| K6011100-400 | 4x400 ul (100 mM) | EUR 282 |
|
Description: Premade ready to use kits will always come in handy. Get your experiment done right form the first try by using a validated kit with perfectly balanced reagents proportions and compatibility and by following a clear protocol. |
||
ACE2 Antibody (biotin) |
||
| 3217-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: ACE2 Antibody: Angiotensin-converting enzyme 2 (ACE2) plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis. Recently. ACE2 has also been shown to be a functional receptor of the SARS coronavirus. Homology modeling shows 2019-nCoV has a similar receptor-binding domain structure as SARS-CoV, which suggests COVID-19 (2019-nCoV) may use ACE2 as a receptor in humans for infection. The normal function of ACE2 is to convert the inactive vasoconstrictor angiotensin I (AngI) to Ang1-9 and the active form AngII to Ang1-7, unlike ACE, which converts AngI to AngII. While the role of these vasoactive peptides is not well understood, lack of ACE2 expression in ace2-/ace2- mice leads to severely reduced cardiac contractility, indicating its importance in regulating heart function. |
||
ACE2 Antibody (biotin) |
||
| 3217-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: ACE2 Antibody: Angiotensin-converting enzyme 2 (ACE2) plays a central role in vascular, renal, and myocardial physiology. In contrast to its homolog ACE, ACE2 expression is restricted to heart, kidney, and testis. Recently. ACE2 has also been shown to be a functional receptor of the SARS coronavirus. Homology modeling shows 2019-nCoV has a similar receptor-binding domain structure as SARS-CoV, which suggests COVID-19 (2019-nCoV) may use ACE2 as a receptor in humans for infection. The normal function of ACE2 is to convert the inactive vasoconstrictor angiotensin I (AngI) to Ang1-9 and the active form AngII to Ang1-7, unlike ACE, which converts AngI to AngII. While the role of these vasoactive peptides is not well understood, lack of ACE2 expression in ace2-/ace2- mice leads to severely reduced cardiac contractility, indicating its importance in regulating heart function. |
||
CX3CR1 Antibody (biotin) |
||
| 2093-biotin-002mg | 0.02 mg | EUR 206.18 |
|
Description: CX3CR1 Antibody: CX3CR1 is one of the chemokine receptors that are required as coreceptors for HIV infection. The genes encoding human, murine, and rat CX3CR1 were cloned and designated V28 and CMKBRL1, CX3CR1, and RBS11, respectively. The encoded seven transmembrane protein was recently identified as the receptor for a novel transmembrane molecule, fractalkine, and renamed CX3CR1. Recently, CX3CR1 was found to serve as a coreceptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by fractokine. CX3CR1 mediates leukocyte migration and adhesion. CX3CR1 is expressed in a variety of human tissues and cell lines. |
||
CX3CR1 Antibody (biotin) |
||
| 2093-biotin-01mg | 0.1 mg | EUR 523.7 |
|
Description: CX3CR1 Antibody: CX3CR1 is one of the chemokine receptors that are required as coreceptors for HIV infection. The genes encoding human, murine, and rat CX3CR1 were cloned and designated V28 and CMKBRL1, CX3CR1, and RBS11, respectively. The encoded seven transmembrane protein was recently identified as the receptor for a novel transmembrane molecule, fractalkine, and renamed CX3CR1. Recently, CX3CR1 was found to serve as a coreceptor for HIV-1 and HIV-2 envelope fusion and virus infection, which can be inhibited by fractokine. CX3CR1 mediates leukocyte migration and adhesion. CX3CR1 is expressed in a variety of human tissues and cell lines. |
||
Anti-human CD14 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00137-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD14 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD11b Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00144-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD11b Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD19 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00154-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD19 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD38 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00193-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD38 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD25 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00214-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD25 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD4 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00344-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD4 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD5 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00480-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD5 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD45 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00555-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD45 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD2 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00570-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD2 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD71 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00591-Biotin | 100µg | EUR 294 |
|
Description: Mouse Monoclonal human CD71 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD62L Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00652-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD62L Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD59 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00914-Biotin | 100µg | EUR 318 |
|
Description: Mouse Monoclonal human CD59 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD117 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01335-Biotin | 100μg | EUR 268.8 |
|
Description: Mouse Monoclonal human CD117 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD32 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01450-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD32 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD90 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01818-Biotin | 100µg | EUR 321.6 |
|
Description: Mouse Monoclonal human CD90 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD7 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01974-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD7 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD235a Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC02184-Biotin | 100µg | EUR 294 |
|
Description: Mouse Monoclonal human CD235a Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD8 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC02236-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD8 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-Human VEGI Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC02402-Biotin | Various Sizes | EUR 596.4 |
|
Description: Mouse Monoclonal Human VEGI Antibody Biotin Conjugated, Flow Validated. Validated in WB and tested in Human. |
||
Anti-human CD3 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC02675-Biotin | 100µg | EUR 182.4 |
|
Description: Mouse Monoclonal human CD3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD20 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC03780-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD20 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD10 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC04065-Biotin | 100µg | EUR 226.8 |
|
Description: Mouse Monoclonal human CD10 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD57 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC09548-Biotin | 100µg | EUR 294 |
|
Description: Mouse Monoclonal human CD57 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human HLA-DR Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00568-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human HLA-DR Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD55/Daf Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC00910-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD55/Daf Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD33/Siglec 3 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01508-Biotin | 100µg | EUR 280.8 |
|
Description: Mouse Monoclonal human CD33/Siglec 3 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
Anti-human CD22/Siglec 2 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01572-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal human CD22/Siglec 2 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
PD1 Antibody [7H6] (biotin) |
||
| RF16003-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins. |
||
PD1 Antibody [7H6] (biotin) |
||
| RF16003-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD-1-null mice who exhibit hyperactivated immune systems and autoimmune diseases. PD-1 is thus one of a growing number of immune checkpoint proteins. |
||
PDL1 Antibody [8E12] (biotin) |
||
| RF16032-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
||
PDL1 Antibody [8E12] (biotin) |
||
| RF16032-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
||
TIGIT Antibody [10B1] (biotin) |
||
| RF16058-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2). |
||
TIGIT Antibody [10B1] (biotin) |
||
| RF16058-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2). |
||
TIM3 Antibody [10C10] (biotin) |
||
| RF16103-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: The immune checkpoint protein TIM3 is a member of the immunoglobulin superfamily and TIM family of proteins that was initially identified as a specific marker of fully differentiated IFN-γ producing CD4 T helper 1 (Th1) and CD8 cytotoxic cells. It is a Th1-specific cell surface protein that regulates macrophage activation and negatively regulates Th1-mediated auto- and alloimmune responses, and is also highly expressed on regulatory T cells, monocytes, macrophages, and dendritic cells (1). TIM3 and PD-1 are co-expressed on most CD4 and CD8 T cells infiltrating solid tumors or in hematologic malignancy in mice; blocking TIM3 in conjugation with a PD-1 blockade increases the functionality of exhausted T cells and synergizes with to inhibit tumor growth (2,3). |
||
TIM3 Antibody [10C10] (biotin) |
||
| RF16103-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: The immune checkpoint protein TIM3 is a member of the immunoglobulin superfamily and TIM family of proteins that was initially identified as a specific marker of fully differentiated IFN-γ producing CD4 T helper 1 (Th1) and CD8 cytotoxic cells. It is a Th1-specific cell surface protein that regulates macrophage activation and negatively regulates Th1-mediated auto- and alloimmune responses, and is also highly expressed on regulatory T cells, monocytes, macrophages, and dendritic cells (1). TIM3 and PD-1 are co-expressed on most CD4 and CD8 T cells infiltrating solid tumors or in hematologic malignancy in mice; blocking TIM3 in conjugation with a PD-1 blockade increases the functionality of exhausted T cells and synergizes with to inhibit tumor growth (2,3). |
||
Datp 100 Mmolar Soln 25Umol |
||
| 28406501 | EACH | EUR 38.76 |
Datp 100 Mmolar Soln 100Umol |
||
| 28406502 | EACH | EUR 124.26 |
Datp 100 Mmolar Soln 500Umol |
||
| 28406503 | EACH | EUR 498.18 |
dATP *100 mM PCR Grade* |
||
| 17250 | 500 uL | EUR 99 |
dATP *100 mM PCR Grade* |
||
| 17251 | 5 mL | EUR 724 |
ALS Style Puck; Qnty 14 |
||
| M-CP-111-035-14 | 14 PUCKS | EUR 4250 |
|
Description: ALS Style Puck; Qnty 14 |
||
TSH (Thyrotrophin) ELISA test |
||
| 14 | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of TSH (Thyrotrophin) |
||
Rat IgG2c-Biotin conjugate (isotype control) |
||
| 20005-14-B | 100 ug | EUR 270 |
Masterflex L/S C-Flex Tubing 50 A L/S 14 25 ft |
||
| WZ-06424-14 | EA | EUR 82.08 |
Keratin 14 (KRT14) Antibody (Biotin) |
||
| 20-abx105606 |
|
|
Matrix metalloproteinase-14 Antibody (Biotin) |
||
| 20-abx105649 |
|
|
Kallikrein 14 (KLK14) Antibody (Biotin) |
||
| 20-abx336218 |
|
|
Tetraspanin-14 (TSPAN14) Antibody (Biotin) |
||
| 20-abx309951 |
|
|
Galectin 14 (LGALS14) Antibody (Biotin) |
||
| 20-abx309964 |
|
|
Calpain 14 (CAPN14) Antibody (Biotin) |
||
| 20-abx316796 |
|
|
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
||
| 3525-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike Antibody (biotin) |
||
| 3525-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Envelope Antibody (biotin) |
||
| 3531-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
||
SARS-CoV-2 (COVID-19) Envelope Antibody (biotin) |
||
| 3531-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
||
| 9099-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
||
| 9099-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
||
| 9103-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
||
SARS-CoV-2 (COVID-19) Nucleocapsid Antibody (biotin) |
||
| 9103-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6). |
||
SARS-CoV-2 (COVID-19) Membrane Antibody (biotin) |
||
| 9157-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
||
SARS-CoV-2 (COVID-19) Membrane Antibody (biotin) |
||
| 9157-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
||
SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin) |
||
| 9083-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike S1 Antibody (biotin) |
||
| 9083-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
||
| 9087-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
||
| 9087-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike 681P Antibody (biotin) |
||
| 9091-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike 681P Antibody (biotin) |
||
| 9091-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
||
| 9123-biotin-002mg | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
||
| 9123-biotin-01mg | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
||
Mouse anti-human CD7 Monoclonal Antibody Biotin Conjugated, Flow Validated |
||
| FC01974-1-Biotin | 100µg | EUR 279.6 |
|
Description: Mouse Monoclonal Mouse human CD7 Antibody Biotin Conjugated, Flow Validated. Validated in Flow Cytometry and tested in Human. |
||
2 Deoxyadenosine 5Triphosphate Disodium Crystalline dATP 250mg |
||
| 27185004 | EACH | EUR 355.68 |
7-Deaza-7-Propargylamino-3'-azidomethyl-dATP |
||
| 17090 | 50 nmoles | EUR 425 |
Human Interferon alpha-14 (IFN-alpha-14) Antibody (Biotin Conjugate) |
||
| 32158-05121 | 150 ug | EUR 442.8 |
14 kDa phosphohistidine phosphatase Antibody (Biotin) |
||
| 20-abx105045 |
|
|
Beta-Defensin 14 (DEFB14) Antibody (Biotin) |
||
| 20-abx105186 |
|
|
Interferon Alpha 14 (IFNA14) Antibody (Biotin) |
||
| 20-abx105568 |
|
|
Glucose Transporter 14 (GLUT14) Antibody (Biotin) |
||
| 20-abx272354 |
|
|
Interferon Alpha 14 (IFNA14) Antibody (Biotin) |
||
| 20-abx304207 |
|
|
Autophagy Related 14 (ATG14) Antibody (Biotin) |
||
| 20-abx316299 |
|
|